AVXL Jan 2025 12.000 call
| Previous close | 0.2700 |
| Open | 0.2700 |
| Bid | 0.3000 |
| Ask | 0.4000 |
| Strike | 12.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.2700 - 0.2700 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.3k |
ZacksAnavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GlobeNewswireAnavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Of
Insider MonkeyAnavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript May 9, 2024 Anavex Life Sciences Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to the Anavex Life Sciences Fiscal 2024 Second Quarter Conference Call. […]
